Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 217

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)

Open access
Nasser, Mouhamad, Larrieu, Sophie, Si-Mohamed, Salim, Ahmad, Kaïs, Boussel, Loic, Brevet, Marie, Chalabreysse, Lara, Fabre, Céline, Marque, Sébastien, Revel, Didier, Thivolet-Bejui, Françoise, Traclet, Julie, Zeghmar, Sabrina, Maucort-Boulch, Delphine, Cottin, Vincent · 2021 · European Respiratory Journal

Abstract

In patients with chronic fibrosing interstitial lung disease (ILD), a progressive fibrosing phenotype (PF-ILD) may develop, but information on the frequency and characteristics of this population outside clinical trials is lacking. We assessed the characteristics and outcomes of patients with PF-ILD other than idiopathic pulmonary fibrosis (IPF) in a real-world, single-centre clinical cohort. The files of all consecutive adult patients with fibrosing ILD (2010–2017) were examined retrospectively for pre-defined criteria of ≥10% fibrosis on high-resolution computed tomography and progressive disease during overlapping windows of 2 years. Baseline was defined as the date disease progression was identified. Patients receiving nintedanib or pirfenidone were censored from survival and progression analyses. In total, 1395 patients were screened; 617 had ILD other than IPF or combined pulmonary fibrosis and emphysema, and 168 had progressive fibrosing phenotypes. In 165 evaluable patients, median age was 61 years; 57% were female. Baseline mean forced vital capacity (FVC) was 74±22% predicted. Median duration of follow-up was 46.2 months. Annualised FVC decline during the first year was estimated at 136±328 mL using a linear mixed model. Overall survival was 83% at 3 years and 72% at 5 years. Using multivariate Cox regression analysis, mortality was significantly associated with relative FVC decline ≥10% in the previous 24 months (p<0.05), age ≥50 years (p<0.01) and diagnosis subgroup (p<0.01). In this cohort of patients with PF-ILD not receiving antifibrotic therapy, the disease followed a course characterised by continued decline in lung function, which predicted mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.02718-2020

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 217

Metadata

Authors
Nasser, M., Larrieu, S., Si-Mohamed, S., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., Thivolet-Bejui, F., Traclet, J., Zeghmar, S., Maucort-Boulch, D., & Cottin, V.
Venue
European Respiratory Journal
Published
2020-09-17
Volume
57
Issue
2
Pages
2002718
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W3087600456
Cited by
217
References
6
FWCI
15.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). https://app.cochat.ai/papers/10.1183/13993003.02718-2020
The paper
Nasser, M., Larrieu, S., Si-Mohamed, S., Ahmad, K., Boussel, L., Brevet, M., Chalabreysse, L., Fabre, C., Marque, S., Revel, D., Thivolet-Bejui, F., Traclet, J., Zeghmar, S., Maucort-Boulch, D., & Cottin, V. (2021). Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). European Respiratory Journal. https://doi.org/10.1183/13993003.02718-2020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.